🔬 Now at Pharmidex: The 8HUM Model
July 21, 2025
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs.
✅ Human-relevant metabolism data
✅ Supports IND-enabling & regulatory studies
✅ Ideal for metabolite profiling, DDI risk & toxicity assessment
By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development.
📩 Contact us to see how 8HUM can support your project.
#Pharmidex #8HUM #DrugMetabolism #DMPK #PreclinicalResearch #InVivoPharmacology #DrugDevelopment
At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.
We’re delighted to share that Martin Barrett , our Head of Business Development, and Rob Jenkins , our Bioanalytical Scientist, will be attending the 51st Open Meeting 2025. This event is a fantastic opportunity to connect with industry leaders, share insights and build new collaborations. Martin and Rob are looking forward to meeting fellow attendees, exchanging ideas and exploring ways to create impactful partnerships that advance drug discovery and development. 🤝 If you’re attending, don’t hesitate to reach out they’ll be happy to connect, discuss your projects, and explore potential synergies.
Designing robust preclinical studies that deliver accurate data the first time. Building flexibility into plans to prevent delays when priorities shift. Coordinating ADME, PK/PD, and toxicology in parallel to save weeks. With over 16,000 projects conducted successfully, work with a proven partner from early discovery to regulatory submission. Our tailored, quality-driven approach keeps your programme on track and your milestones within reach. Let’s make your IND deadline a milestone you hit with confidence
